Has Peter Kelley received payments from drug or device companies?

Yes. Drug and device makers reported $998 in general payments to Peter Kelley across 57 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Peter Kelley did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Peter Kelley come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Peter Kelley

Family · Corfu, NYNPI 1689630725

Payments from drug & device makers

$998in general payments, 2019–2025

Across 57 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$200
Novo Nordisk$158
Bayer$117
Insulet Corporation$88
Sanofi-aventis U.S. LLC$67
Otsuka America Pharmaceutical, Inc.$66
plus $302 from 12 others

What the payments were for

Food & beverage$998100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	13	$200
Novo Nordisk	10	$158
Bayer	6	$117
Insulet Corporation	4	$88
Sanofi-aventis U.S. LLC	3	$67
Otsuka America Pharmaceutical, Inc.	3	$66
Phathom Pharmaceuticals, Inc.	4	$47
Cumberland Pharmaceuticals, Inc.	2	$39
Axsome Therapeutics, Inc.	2	$37
Corcept Therapeutics	2	$31
Edwards Lifesciences	1	$27
AstraZeneca	1	$24
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	1	$20
Cranial Technologies, Inc	1	$16
Merck	1	$16
IBSA Pharma Inc.	1	$15
Boehringer Ingelheim	1	$15
ARS Pharmaceuticals Operations, Inc.	1	$15

How this compares

$998 in reported general payments places this provider in the 70th percentile of 8,883 family providers in New York.

See all family providers in New York →

Medicare billing

Part B allowed, 2024

$14,906

Medicare patients

121

Services billed

350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Methylprednisolone	14	$96
Cephalexin	11	$61

Paid to pharmacies, not to this prescriber.

Other family in Corfu

Christina NalboneNew York$197K
Casey GrilloNew York$191K
Suzanne WilsonIthaca$179K
Jonathan LesuerSyracuse$172K
Sheri HillNorth Syracuse$165K
Cathrine CurtinBronxville$155K
Mary Sullivan-WhalenNew York$137K
Sarah AljahmiRockville Centre$87K
John de OcaStaten Island$86K
Fara StrickerGlen Oaks$85K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →